AbbVie (ABBV) Receivables (2012 - 2026)

AbbVie has disclosed Receivables across 15 years of filings, most recently posting $12.5 billion for Q1 2026.

• In Q1 2026, Receivables changed 0.02% year-over-year to $12.5 billion; the TTM figure through Mar 2026 stood at $12.5 billion (changed 0.02% YoY), while the FY2025 annual figure was $12.6 billion, up 15.29% from the prior year.
• Receivables eased to $12.5 billion in Q1 2026, from $12.6 billion in the prior quarter.
• Over the last five years, Receivables for ABBV reached as high as $12.8 billion in Q3 2025 and fell as low as $10.7 billion in Q1 2022.
• The 5-year median for Receivables is $11.5 billion (2023), against an average of $11.7 billion.
• Annual changes were most pronounced in 2022 — Receivables increased 15.75% — and 2024, when it decreased 2.12%.
• A 5-year view of Receivables shows it stood at $11.3 billion in 2022, then fell by 0.88% to $11.2 billion in 2023, then slipped by 2.12% to $10.9 billion in 2024, then climbed by 15.29% to $12.6 billion in 2025, then decreased by 0.87% to $12.5 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $12.5 billion, $12.6 billion, and $12.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.